Lv2
110 积分 2024-05-02 加入
Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib
1天前
待确认
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
1个月前
已完结
Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients
2个月前
已完结
KDIGO Clinical Practice Guidelines for Acute Kidney Injury
2个月前
已完结
Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia
5个月前
已完结
Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia
6个月前
已完结
Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study
6个月前
已关闭
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma
6个月前
已完结
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects
1年前
已完结
Prognostic value of the mutation types and dynamics of FLT3‐ITD in acute myeloid leukemia
1年前
已完结
皖公网安备34019202002308
